CSIMarket
 
Nuvation Bio Inc   (NYSE: NUVB)
Other Ticker:  
 
 
Price: $2.4500 $0.04 1.660%
Day's High: $2.47 Week Perf: 2.08 %
Day's Low: $ 2.35 30 Day Perf: -15.22 %
Volume (M): 1,952 52 Wk High: $ 4.16
Volume (M$): $ 4,782 52 Wk Avg: $2.75
Open: $2.45 52 Wk Low: $1.57



 Market Capitalization (Millions $) 670
 Shares Outstanding (Millions) 274
 Employees 46
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -532
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 0

Nuvation Bio Inc
Nuvation Bio Inc. is a biopharmaceutical company that specializes in the research, development, and delivery of innovative therapies for the treatment of chronic diseases. The company's mission is to improve the lives of patients by creating transformative medicines that address unmet medical needs.

Nuvation Bio's primary focus is on the development of a new class of drugs known as engineered decoy receptors. These drugs are designed to target the root cause of chronic diseases by neutralizing specific proteins in the body that contribute to disease progression. By doing so, the company hopes to provide patients with more effective and durable treatments that have fewer side effects than traditional drugs.

The company was founded in 2018 by several renowned scientists and biotech entrepreneurs, including Dr. George Gilliland and Dr. Robert Tjian. Dr. Gilliland is a leading expert in protein engineering and has led the development of several successful biotech companies, while Dr. Tjian is a renowned biochemist and former president of the Howard Hughes Medical Institute.

Since its inception, Nuvation Bio has made significant progress in the development of its platform technology and drug candidates. The company recently announced promising preclinical data for its lead program, NB-101, which targets a protein involved in the development of fibrotic diseases.

In addition to its internal drug development efforts, Nuvation Bio has established several partnerships and collaborations with other leading biopharmaceutical companies. These relationships provide the company with access to new technologies and expertise, which it can leverage to accelerate the development of its pipeline.

Overall, Nuvation Bio Inc. is an innovative biopharmaceutical company that is well-positioned to make a significant impact in the field of chronic disease treatment. The company's platform technology and pipeline of drug candidates hold great promise for improving the lives of millions of patients worldwide.


   Company Address: 1500 Broadway New York 10036 NY
   Company Phone Number: 208-6102   Stock Exchange / Ticker: NYSE NUVB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        5.33% 
BMY   -1.92%    
JNJ        1.17% 
LLY        7.6% 
MRK   -10.04%    
PFE   -2.11%    
• View Complete Report
   



Business Update

Advancements in ROS1-Positive Non-Small Cell Lung Cancer Treatment Nuvation Bios Taletrectinib and the Expanded Acce...

Published Mon, Feb 3 2025 7:31 PM UTC

Abstract Nuvation Bio s recent initiatives surrounding the investigational drug taletrectinib illustrate a commitment to addressing significant unmet medical needs in oncology, particularly for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). The company s launch of an Expanded Access Program (EAP) in the U.S. and the promising data from the Phase 2...

Business Update

Nuvation Bio Striving for Oncology Innovation Amid Financial Headwinds,

Published Thu, Nov 7 2024 4:36 AM UTC

Nuvation Bio: Navigating Financial Challenges While Pursuing Oncology Breakthroughs Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage global biopharmaceutical company, recently presented its financial results for the third quarter of 2024, showcasing the challenges and aspirations that define its journey in the competitive oncology landscape. The company, renowned for ...

Business Update

Positive Pooled Data from Nuvation Bios TRUST-I and TRUST-II Studies Highlight Taletrectinibs Best-in-Class Potential...

Published Mon, Sep 16 2024 12:47 AM UTC

Unveiling Taletrectinib s Potential: Nuvation Bio s Success in Advanced ROS1-Positive NSCLC Treatment Positive Data from Phase 2 TRUST-I and TRUST-II StudiesNuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company renowned for its innovative oncology research, has announced promising results from its Phase 2 TRUST-I and TRUST-II studies focused on taletrectinib, a...

Business Update

Nuvation Bio Showcases Promising Taletrectinib Data Ahead of NDA Submission, Reports Positive Financial Results in 20...

Published Sat, Sep 14 2024 7:47 AM UTC

Nuvation Bio s Advancements in Oncology: Taletrectinib Data Paves the Way for New Drug Application, Financial Outlook Promises GrowthNuvation Bio Inc. (NYSE: NUVB), a pioneering biopharmaceutical company dedicated to addressing critical unmet needs in oncology, is making significant strides in its development of innovative cancer therapies. Recently, the company announced p...

Business Update

In the ever-evolving landscape of oncology therapeutics, Nuvation Bio Inc. (NYSE NUVB) emerges as a notable...

Published Mon, Aug 5 2024 12:47 PM UTC

Nuvation Bio: Pioneering Pathways in Oncology with Promising Second Quarter Results In the ever-evolving landscape of oncology therapeutics, Nuvation Bio Inc. (NYSE: NUVB) emerges as a notable player, demonstrating significant advancements and a commitment to addressing some of the most pressing unmet needs in cancer treatment. As a late clinical-stage biopharmaceutical comp...







Nuvation Bio Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com